| [11C]AZ1419 3391 + Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Accelerated Hypofractionated Radiation Therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Allogeneic genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendroglioma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendroglioma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Autologous genetically modified gamma-delta T cells for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CTX-471 + Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dabrafenib, trametinib, nivolumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-escalated radiation therapy for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dose-intensified Photon Beam Radiation Therapy for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Educational and Media Intervention for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eflornithine for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Fluzoparib with Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IA Carboplatin + IA Caelyx for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IA Carboplatin + IA Etoposide Phosphate for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1 peptide vaccine for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1-vac for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1R132H peptide vaccine for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| IDH1R132H peptide vaccine + AVELUMAB for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Idroxioleate Sodium for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ipatasertib + atezolizumab for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JBI-778 for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| JK-1201I + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low-dose Radiotherapy + SINTILIMAB for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| M032 + PEMBROLIZUMAB for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| M032 + PEMBROLIZUMAB for gliosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin hydrochloride for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for glioblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Onfekafusp alfa for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Optune System + PEMBROLIZUMAB + Temozolomide for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Datopotamab Deruxtecan for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Palacaparib + Temozolomide for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Perillyl alcohol for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Placebo + Metformin for medulloblastoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab govitecan for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Selinexor for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Srs + retifanlimab + ragifilimab for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Subventricular Zone radiation for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tarlatamab + Temozolomide for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Temozolomide for glioblastoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tovecimig for glioblastoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib + DABRAFENIB for glioma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Trametinib and Nivolumab for glioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vebreltinib for glioblastoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|